Atrial Fibrillation
Conditions
Interventions
Valsartan40-80mg daily, during the study period.
Control
Sponsors
Department of Cardiovascular Medicine Tohoku University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria (1) symptomatic AF patients with at least two kinds of drug-resistance (2)Patients who are aged 30 years or older and less than 70 years at the entry (3) Patients without ischemic cardiovascular disease, valvular disease and cardiomyopathy.
Exclusion criteria
Exclusion criteria: (1)Patients who have renal dysfunction (serum creatinine>=3.0mg/dL or those who are receiving chronic hemodialysis (2) History of drug hypersensitivity to angiotensine II receptor blocker. (3)Patients who have severe liver dysfunction (4)Patents with cerebrovasucular disease (5)History of angioedema (6)History of malignant tumor or life threatening illness of poor prognosis (7)Pregnant or possibly pregnant patients (8)Patents after Cardiovascular surgery (9)Other patients deemed unsuitable as subjects of the study by the treating physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| A composite of all - reverse remodeling of left atrium and recurrence of atrial fibrillation. | — |
Countries
Japan
Contacts
Public ContactKoji Kumagai
Tohoku University Graduate School of Medicine Department of Cardiovascular Medicine
Outcome results
None listed